Logo


Natco Pharma upbeat over US Patent Office's ruling on two of Copaxone patents

In August 2014, Mylan had filed the abbreviated new drug application for multiple sclerosis drug Copaxone 40 mg/ml with the US FDA

Natco Pharma

Hyderabad-basedNatcoPharmaonThursdayannouncedthattheUSPatentandTrademarkOffice(PTO)hasruledinfavourofitsmarketingpartner,Mylan,initsnewtrialproceedingsonpatentabilityandfoundallclaimsoftworelatedCopaxone40mg/mlpatentsasunpatentable. InAugust2014,Mylanhadfiledtheabbreviatednewdrugapplication(ANDA)formultiplesclerosisdrugCopaxone40mg/mlwiththeUSFoodandDrugAdministration(USFDA),besideschallengingthepatentclaimsoftheTevawhichownsthedrug. TheANDAfilingbyMylanpertainstothelongeractingCopaxonewhile ...